The new EU4Health Joint Action CAPRICORD – set out on the website of the Agency for Health Technology Assessment and Tariff System (Agencja Oceny Technologii Medycznych i Taryfikacji, AOTMiT) under the title CAPRICORD – Competent Authorities for Pricing and Reimbursement to coordinate Involvement of clinical experts and patients, to manage uncertainty and the challenges associated to ORphan medicinal products – started on 1 November 2025 and runs until 31 October 2028. The initiative gives the Hungarian National Health Insurance Fund Administration (Nemzeti Egészségbiztosítási Alapkezelő, NEAK) the coordinator role, which shifts agenda‑setting power away from the larger western European markets that have traditionally driven cross‑border pricing alliances.
According to the news item El ISCIII acoge el lanzamiento de CAPRICORD, proyecto europeo sobre acceso a medicamentos, productos y tecnologías sanitarias (The ISCIII hosts the launch of CAPRICORD, a European project on access to medicines, products and health technologies), the Carlos III Health Institute (Instituto de Salud Carlos III, ISCIII) positions CAPRICORD as the main EU‑backed forum for aligning payer responses to uncertainty around orphan drugs and other low‑prevalence technologies. The consortium will test ways to move from supply‑driven to needs‑driven pricing structures and to tighten the link between clinical uncertainty and price concessions.
A work package led by AOTMiT maps how patients and clinicians are currently involved in health technology assessment and reimbursement decisions, stress‑tests those models, then proposes standard consultation templates and guidance. EURORDIS – Rare Diseases Europe is a consortium partner, which gives organised patient groups structured access to payer deliberations that have historically been opaque.
If member states use CAPRICORD outputs to embed common approaches into national rules, companies will face more convergent expectations on evidence packages, managed entry terms and transparency across at least eleven pricing and reimbursement systems, with orphan portfolios most exposed to the new scrutiny.
Source: Agency for Health Technology Assessment and Tariff System (Agencja Oceny Technologii Medycznych i Taryfikacji, AOTMiT)
Link: CAPRICORD – Competent Authorities for Pricing and Reimbursement to coordinate Involvement of clinical experts and patients, to manage uncertainty and the challenges associated to ORphan medicinal products
Date: 22 December 2025
